ADVM News
Archived Headlines
- Avalanche Biotechnologies increases range to $16 to $17 07/30/14
- 22 US IPOs planned for the week of Jul 28 07/28/14
- July biotech blitz and the upcoming eye, ear and nose IPOs 07/22/14
- Eye disease biotech Avalanche Biotechnologies sets terms for $76 million IPO 07/21/14
- Eye disease biotech Avalanche Biotechnologies files for a $86 million IPO 06/30/14
It's electric: Spark Therapeutics increases proposed IPO deal size by 48% to $130 million
Spark Therapeutics, which is developing gene therapy treatments for orphan retinal dystrophies, raised the proposed deal size for its upcoming IPO on Wednesday. The Philadelphia, PA-based company now plans to raise $130 million by offering 6.5 million...read more
US IPO Pricing Recap: 15 IPOs in the most active week since 2007; 66% ended at or below IPO price
15 companies had initial public offerings and raised $6.4 billion this week, making it the most active week in the IPO market since 2007. Including deals that priced yesterday and began trading today, July saw 34 IPOs, a post-tech bubble record....read more
IPO market brought down by biotech wreck and market sell off
Last night 12 IPOs were expected to price, but only 8 did. Two deals were postponed: extended release biotech Mapi-Pharma (MAPI) and cardiovascular diagnostic firm Lantheus (LNTH). Two deals were delayed a day: osteoporosis patch biotech Zosano...read more
Avalanche Biotechnologies prices upsized IPO at $17, the high end of the upwardly revised range
Avalanche Biotechnologies, an early-stage biotech developing a gene therapy for wet AMD, raised $102 million by offering 6.0 million shares at $17, the high end of its upwardly revised $16 to $17 range. The company originally filed to offer 5.4 million shares at...read more